Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Oct 24:14:164.
doi: 10.1186/1471-2466-14-164.

Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus

Craig P Hersh  1 , Barry J Make, David A Lynch, R Graham Barr, Russell P Bowler, Peter M A Calverley, Peter J Castaldi, Michael H Cho, Harvey O Coxson, Dawn L DeMeo, Marilyn G Foreman, MeiLan K Han, Benjamin J Harshfield, John E Hokanson, Sharon Lutz, Joe W Ramsdell, Elizabeth A Regan, Stephen I Rennard, Joyce D Schroeder, Frank C Sciurba, Robert M Steiner, Ruth Tal-Singer, Edwin van Beek Jr, Edwin K Silverman, James D Crapo; COPDGene and ECLIPSE Investigators
Collaborators, Affiliations
Clinical Trial

Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus

Craig P Hersh et al. BMC Pulm Med. .

Abstract

Background: Chronic obstructive pulmonary disease (COPD) has been classically divided into blue bloaters and pink puffers. The utility of these clinical subtypes is unclear. However, the broader distinction between airway-predominant and emphysema-predominant COPD may be clinically relevant. The objective was to define clinical features of emphysema-predominant and non-emphysematous COPD patients.

Methods: Current and former smokers from the Genetic Epidemiology of COPD Study (COPDGene) had chest computed tomography (CT) scans with quantitative image analysis. Emphysema-predominant COPD was defined by low attenuation area at -950 Hounsfield Units (LAA-950) ≥10%. Non-emphysematous COPD was defined by airflow obstruction with minimal to no emphysema (LAA-950 < 5%).

Results: Out of 4197 COPD subjects, 1687 were classified as emphysema-predominant and 1817 as non-emphysematous; 693 had LAA-950 between 5-10% and were not categorized. Subjects with emphysema-predominant COPD were older (65.6 vs 60.6 years, p < 0.0001) with more severe COPD based on airflow obstruction (FEV1 44.5 vs 68.4%, p < 0.0001), greater exercise limitation (6-minute walk distance 1138 vs 1331 ft, p < 0.0001) and reduced quality of life (St. George's Respiratory Questionnaire score 43 vs 31, p < 0.0001). Self-reported diabetes was more frequent in non-emphysematous COPD (OR 2.13, p < 0.001), which was also confirmed using a strict definition of diabetes based on medication use. The association between diabetes and non-emphysematous COPD was replicated in the ECLIPSE study.

Conclusions: Non-emphysematous COPD, defined by airflow obstruction with a paucity of emphysema on chest CT scan, is associated with an increased risk of diabetes. COPD patients without emphysema may warrant closer monitoring for diabetes, hypertension, and hyperlipidemia and vice versa.

Trial registration: Clinicaltrials.gov identifiers: COPDGene NCT00608764, ECLIPSE NCT00292552.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Frequencies of the “pink puffer” and “blue bloater” subtypes of COPD by severity of airflow obstruction. See Methods for definitions.
Figure 2
Figure 2
Chest CT scans from COPDGene subjects demonstrating emphysema-predominant and non-emphysematous COPD. (A) Emphysema-predominant: FEV1 55.8% predicted, 29.0% emphysema. (B) Non-emphysematous: FEV1 55.3% predicted, 4.2% emphysema.
See this image and copyright information in PMC

References

    1. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2012;187(4):347–365. doi: 10.1164/rccm.201204-0596PP. - DOI - PubMed
    1. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, Macnee W, Make BJ, Rabe KF, Rennard SI, Sciurba FC, Silverman EK, Vestbo J, Washko GR, Wouters EF, Martinez FJ. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182(5):598–604. doi: 10.1164/rccm.200912-1843CC. - DOI - PMC - PubMed
    1. Nocturnal Oxygen Therapy Trial Group Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med. 1980;93(3):391–398. doi: 10.7326/0003-4819-93-3-391. - DOI - PubMed
    1. Medical Research Council Working Party Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet. 1981;1(8222):681–686. - PubMed
    1. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood DE. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348(21):2059–2073. doi: 10.1056/NEJMoa030287. - DOI - PubMed
Pre-publication history
    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2466/14/164/prepub

Publication types

Associated data